Proteome-based Personalized Immunotherapy of Glioblastoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Blokhin's Russian Cancer Research Center
Russian Foundation of Technological Development
The Serbsky State Scientific Center for Social and Forensic Psychiatry
Autonomous Non-commercial organization "National Institute of Regenerative Medicine
SRC Bioclinicum
Information provided by (Responsible Party):
NeuroVita Clinic
ClinicalTrials.gov Identifier:
NCT01759810
First received: December 28, 2012
Last updated: January 30, 2013
Last verified: January 2013
  Purpose

Trial Hypothesis: Acute, progressing lethal neurooncological process can be transferred into chronic and non-lethal, the survival rates and life quality can be improved by of control of tumor cells (TCs) quantity and targeted regulation of effector functions of tumor stem cells (TSCs).

Brief Description:

The first line therapy of glioblastoma multiforme (GBM) involves allogeneic haploidentical hematopoietic stem cells (HSCs), dendritic vaccine (DV) and cytotoxic lymphocytes (CTLs).

TCs and TSCs are isolated from GBM sample. Dendritic cells are isolated from peripheral blood mononuclear cells and cultured. Tumor sample provides tumor specific antigens to prepare DV. CTLs are obtained from peripheral blood after DV administrations. HSCs are harvested from closely related donor after granulocyte-colony-stimulating factor (G-CSF) administration.

Allogeneic HSCs are administered intrathecally 5 times every 2 weeks, at day 1, 14, 28, 42, 56. DV is given 3 times every 2 weeks (day 14, 28, 42) subcutaneously in four points. CTLs are administered every 2 weeks for 3 months, then 3 times every 1 month intrathecally. Six months after the therapy completion, the efficiency is evaluated and the cohort demonstrating efficiency continues the therapy, while cohort demonstrating no efficiency is transferred to active comparator arm.

Second line therapy involves DV with recombinant proteins, CTLs and autologous HSC with modified proteome. Autologous HSCs are mobilized by G-CSF.

Carcinogenesis-free intracellular pathways of signal transduction able to respond to targeted regulation of therapeutic cell systems with specific properties, are detected in TSCs using complete transcriptome profiling of gene expression, proteome mapping and profiling of proteins, bioinformation and mathematical analysis and mathematical modeling of protein profiles. To find key oncospecific proteins in TSCs and TCs, the targets for TSCs regulation are detected, as well as protein ligands able to regulate reproductive and proliferative properties of TSCs.

Using these data of TCs and TSCs proteins, the cell preparations to initiate adoptive immune response are prepared: DV loaded with recombinant proteins analogous to key tumor antigens, CTLs and autologous proteome-modified HSCs.

Autologous proteome-modified HSCs, DV and CTLs are administered as in the first line therapy.


Condition Intervention Phase
Glioblastoma
Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes
Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Proteome-based Personalized Immunotherapy of Malignant Brain Tumors

Resource links provided by NLM:


Further study details as provided by NeuroVita Clinic:

Primary Outcome Measures:
  • All cause mortality [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Complete disappearance of all tumor foci [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • reduction of tumor size by no less than 50% and absence of new foci [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: December 2012
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: allogeneic stem cells Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes
3 ml suspension of allogeneic haploidentical hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
Active Comparator: autologous stem cells Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Morphologically confirmed glioma (in case of relapse and impossibility of biopsy, diagnosis based on radiological and other diagnostic methods)
  • Refractory to the first and following conventional lines of chemo- and radiotherapy, if their removal is impossible.
  • Glioblastoma relapses after at least one line of conventional chemo- and radiotherapy, if their removal is impossible
  • Availability of HLA partially compatible related donor
  • Life expectancy of no less than 3 months
  • Absence of severe decompensated organ dysfunction
  • Informed consent of the patient or their parents
  • Informed consent of the donor

Exclusion Criteria:

  • Failure to meet one of the inclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01759810

Locations
Russian Federation
ZAO "NeuroVita Clinic of Interventional and Restorative Neurology and Therapy"
Moscow, Russian Federation, 115478
Sponsors and Collaborators
NeuroVita Clinic
Blokhin's Russian Cancer Research Center
Russian Foundation of Technological Development
The Serbsky State Scientific Center for Social and Forensic Psychiatry
Autonomous Non-commercial organization "National Institute of Regenerative Medicine
SRC Bioclinicum
Investigators
Principal Investigator: Andrey S. Bryukhovetskiy, MD ZAO "NeuroVita Clinic of Interventional and Restorative Neurology and Therapy"
  More Information

No publications provided

Responsible Party: NeuroVita Clinic
ClinicalTrials.gov Identifier: NCT01759810     History of Changes
Other Study ID Numbers: GBM/2012
Study First Received: December 28, 2012
Last Updated: January 30, 2013
Health Authority: Russia: Ethics Committee of FGBU "Federal Research Center for Specialized Types of Medical Care and Medical Technologies" of FMBA
Russia: Scientific Board of FGBU "Federal Research Center for Specialized Types of Medical Care and Medical Technologies" of FMBA
Russia: Ethics Committee of FGBU N.N. Blokhin Russian Cancer Research Centre of RAMN
Russia: Scientific Board of FGBU N.N. Blokhin Russian Cancer Research Centre of RAMN

Keywords provided by NeuroVita Clinic:
Glioblastoma, recurrent glioblastoma

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on July 22, 2014